Unknown PHASE4 INTERVENTIONAL 2-arm NCT04585997

Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - Choosebetweenamab.

How to Choosebetweenamab for Severe Asthma, Comparing Treatment With Mepolizumab and Omalizumab for Patients With Severe Allergic and Eosinophilic Asthma.

Sponsor: GlaxoSmithKline

Conditions Asthma Eosinophilic Asthma

Interventions Mepolizumab Omalizumab

Updated 5 times since 2020 Last updated: Oct 6, 2020 Started: Nov 3, 2018 Primary completion: Jun 30, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04585997, this PHASE4 trial focuses on Asthma and Eosinophilic Asthma and remains ongoing. Sponsored by GlaxoSmithKline, it has been updated 5 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2023 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2023 [monthly]

Recruiting PHASE4
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
University of Newcastle, Australia

Data source: University of Newcastle, Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Lambton, Australia